ASMB - Assembly Bio Operating income before deduction of amortization

Graphic logo of assemblybio.com (ASMB)

Assembly Biosciences is battling powerful corporations within the high-risk hepatitis therapy sector. On GURU.Markets, the actual size of operating profit reflects the asset's dynamics, where the value of 0.00 serves as the current indicator. The firm's resilience is based on an R&D partnership with Gilead to develop new inhibitors; however, the lack of sales during the testing phase is converting investments into rising costs.

ASMB (Assembly Biosciences, Inc.) Operating profit EBITDA history from 11/23/2025 to 11/10/2026

Assembly Biosciences, Inc. (ASMB) - metric breakdowns and financial figures

- stock price and consensus target price:
Price Chart Assembly Corp|ASMB - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Assembly Biosciences|ASMB - Real Price to Acquire Entire Company
- balance sheet equity data:
Net Assets per Single Share Assembly Biosciences|ASMB - Book Capitalization|Market-to-Book Ratio assemblybio.com|ASMB - Aggregate Company Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Assembly Biosciences|ASMB - Long-Term Debt to Capital|Short-Term Debt to Capital Assembly Bio|ASMB - Company Debts|Debts to Net Assets Assembly Biosciences|ASMB - Company Long-Term Debt|Short-Term Debt Volume Assembly Biosciences|Immediate Liquidity assemblybio.com
- net income and valuation multiples indicators:
ASMB - Company Net Income|Future Profit Assembly Biosciences|ASMB - P/E Multiple|Future Price to Earnings assemblybio.com|ASMB - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Assembly Biosciences|ASMB - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Assembly Biosciences|ASMB - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months assemblybio.com|ASMB - Earnings growth in current year|Net earnings per share growth forecast for next year Assembly Biosciences
Analysis of all company metrics:ASMB Assembly Corp
Brand item of Assembly Biosciences, Inc.

Amidst fierce competition with pharmaceutical behemoths to develop a hepatitis B cure, the financial stability of Assembly Biosciences (ASMB) depends on the efficiency of its cost management. By analyzing the current EBITDA, investors assess the business's ability to generate cash flow before taxes and interest, which determines the company's liquidity and its risk appetite in the scientific race.

Competitors of Assembly Biosciences (ASMB)

Arrowhead Corp - Profit before payment of interest, taxes and amortization|Mirum Pharmaceuticals - Operating profit EBITDA|Operating income before deduction of amortization Dynavax Technologies Corp DVAX|ABUS (Arbutus Biopharma Corporation) - Operating profit before deduction of amortization|IVA (Inventiva SA) - Profit before payment of interest, taxes and amortization|GYRE (Gyre Corp) - Operating profit EBITDA|Profit before interest, taxes and amortization Galectin GALT|Profit before payment of interest, taxes and amortization Genfit S.A. (GNFT)|DRRX (durect.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA ALGS (Aligos Therapeutics, Inc.)|Operating profit EBITDA BioVie Inc BIVI|GLMD - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization ENDRA Corp NDRA|hepionpharma.com (HEPA) - Profit before payment of interest, taxes and amortization